PDF
Citation
Print
On 3 December 2021, 718,142 new cases of the coronavirus disease 2019 (COVID-19) were reported just in one day globally, reaching 265 million cumulative cases and 5.24 million total deaths.1 In Korea, the Korea Disease Control and Prevention Agency (KDCA) reported 5,817 new daily cases and 523,088 cumulative ones on December 13, 2021. Daily deaths were 80 and cumulative deaths were 4,293 with 0.82% mortality rate due to COVID-19.2 The KDCA report noted 114 confirmed cases with the omicron variant in Korea. The fact that COVID-19 cases are increasing though the vaccinated population is over 80% upsets the Government officials and health professionals in Korea. Most European countries and the U.S. are facing the same paradoxical problem in December 2021. Munro et al.3 compared anti- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike IgG antibodies, pseudovirus neutralizing antibodies, and cellular responses of spot forming cells after the third shot for healthy adults with 2 doses of vaccination with ChAdOx-nCov19 (AstraZeneca) or BNT162b2 (Pfizer-BioNTech) vaccines in the U.K. The clinical trial data demonstrated that both humoral and cellular immune responses were reduced 70–84 days after the second dose but the immune responses were significantly increased by the third dose. The trial data demonstrated low level of protective immunity to delta variant infection after the second vaccination, shedding light on the breakthrough infections in countries with high vaccination rate.3
Many Korean experts have explored and publicized clinical and epidemiological characteristics of COVID-19. Although it is difficult to estimate the global publication record on COVID-19, we performed searches of related articles on PubMed (https://pubmed.ncbi.nlm.nih.gov/) and KoreaMed (https://www.koreamed.org/). We counted COVID-19 publications by Korean authors searchable on PubMed from January 1, 2020 to August 19, 2021 and KoreaMed from January 1, 2020 to July 29, 2021. The articles were searched by 4 keywords; COVID-19, coronavirus disease (or corona virus disease), SARS-CoV-2, and severe acute respiratory syndrome.
Since the report of the first COVID-19 patient in Korea in the Journal of Korean Medical Science (JKMS),4 a total of 230 articles had been published in the same journal by December 4, 2021: 9 reviews, 7 special articles, 106 original research articles, 40 brief communications, 21 case reports, 8 editorials, 23 opinion pieces, 1 image, 4 cartoons, and 11 letters.5
Table 1 summarizes PubMed and KoreaMed recorded publications on COVID-19. A total of 83,549 publications on COVID-19 were searchable on PubMed, including 1,875 (2.2%) authored by Korean researchers. The 1,875 articles were published in 673 journals, 67 of which were based in Korea. During the covered period, 176 articles on COVID-19 originated from JKMS (0.21% of whole PubMed records and 9.4% of total Korean publications).
The KoreaMed platform indexed 766 articles on COVID-19 from 141 journals, with 612 authored by Koreans. In KoreaMed, 165 JKMS articles were recorded (Table 1). The authors’ nationality and related document counts in KoreaMed are summarized in Supplementary Table 1.
The top 20 journals that published COVID-19 articles of Korean authors are listed in Table 2. The JKMS had published most COVID-19 articles covered by both platforms. The two platforms displayed differing records for same journals probably due to different time lags of each indexing system. The PubMed data indicated that more than 100 articles had been published by Korean authors monthly since March 2020 (Fig. 1).
Some researchers published their articles in the top-ranked medical journals; 5 publications in the New England Journal of Medicine, 5 Lancet and 21 Lancet sister journals, 2 JAMA and 5 JAMA Network journals, 6 BMJ, and 4 BMJ Open. Half of these publications were coauthored by foreign collaborators. These publications reflected top-quality contributions of Korean authors who take part in the global academic competition.
The data of COVID-19 publications demonstrate just one aspect of research activities in Korea. Korean researchers had published 2.2% articles of the PubMed records from January 2020 to August 19, 2021. Along with the top-ranked general medical journals, the JKMS is the preferred target for Korean researchers with interest in COVID-19.
One of the main advantages of JKMS is its weekly publication schedule.6 The JKMS issues are now published every Monday, enabling rapid dissemination of cutting-edge knowledge in medicine and public health. All COVID-19 submissions have been separately handled in line with an urgently designed fast-track processing, editing, and publishing strategy. Such strategy coupled with advanced global visibility positions the JKMS among the best target journals amidst the ongoing COVID-19 pandemic. Notably, the JKMS is listed by the Directory of Open Access Journals (DOAJ) and promoted by its official Twitter channel, both contributing to the openness, citability, and societal impact. As an example, one article that reported early epidemiological characteristics of COVID-19 in Korea had been cited 251 times on Web of Science, the highest citation record for related JKMS articles (as of December 8, 2021).7 There are also 6 related JKMS articles with more than 100 citations (Supplementary Table 2).4891011121314
The JKMS is distinguished as one of the most reputable general medical journals with membership in the International Committee of Medical Journal Editors (ICMJE). Articles covering medical aspects of COVID-19 perfectly fall within the scope of interests of the journal, contributing to the global evidence accumulation. The JKMS invites COVID-19 submissions from diverse medical fields such as internal medicine, public health, chemotherapy, surgery, laboratory medicine, epidemiology, immunology, pediatrics, psychiatry, and basic research.
In conclusion, Korean authors actively contribute to the global publication record on COVID-19. They publish more than 100 related articles monthly. The JKMS is the main target for Korean researchers who aim to publish their most impactful COVID-19 articles.
XML Download